Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN II 15% IN PLASTIC CONTAINER vs AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Amino acids provide substrates for protein synthesis, counteract negative nitrogen balance, and maintain muscle mass. Dextrose supplies calories for energy metabolism, and electrolytes correct or prevent imbalances.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
1-2 L/day intravenously, infused at a rate of 1-2 mL/kg/hour (50-100 mL/hour) for a 70 kg adult, adjusted based on nitrogen and caloric needs.
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Variable; amino acids have half-lives of minutes to hours depending on metabolic demand and renal function. Dextrose has a half-life of 15-20 minutes under normal conditions. In renal impairment, half-life of amino acid byproducts may prolong.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Urea (from amino acid metabolism) is excreted renally. Electrolytes and dextrose metabolites are eliminated via renal and respiratory routes. No significant biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution